Citigroup Inc Cerevel Therapeutics Holdings, Inc. Put Options Transaction History

Citigroup Inc

  • $169 Billion
  • Q3 2024

Put Options

3 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q4 2023

Feb 09, 2024
BUY
$20.27 - $42.44 $606,073 - $1.27 Million
29,900 New
29,900 $1.27 Million
Q1 2023

May 11, 2023
BUY
$22.82 - $35.32 $150,612 - $233,112
6,600 Added 28.21%
30,000 $731,000
Q4 2022

Feb 09, 2023
BUY
$25.35 - $31.96 $593,190 - $747,864
23,400 New
23,400 $738,000

Others Institutions Holding CERE

# of Institutions
9
Shares Held
5.01M
Call Options Held
3.3K
Put Options Held
0
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email